BioXcel Therapeutics Inc
F:BX2
BioXcel Therapeutics Inc
F:BX2
Price:
2.56
EUR
Market Closed
Market Cap:
€96.1m
Balance Sheet
Balance Sheet Decomposition
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
Balance Sheet Decomposition is not available for
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
Balance Sheet
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
Currency: USD
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
0
|
1
|
43
|
32
|
213
|
233
|
194
|
65
|
30
|
|
| Cash Equivalents |
0
|
0
|
1
|
43
|
32
|
213
|
233
|
194
|
65
|
30
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
|
| Other Current Assets |
0
|
0
|
0
|
1
|
2
|
4
|
4
|
7
|
5
|
7
|
|
| Total Current Assets |
0
|
0
|
1
|
43
|
34
|
217
|
237
|
203
|
72
|
37
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
2
|
3
|
3
|
2
|
1
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
2
|
3
|
3
|
2
|
1
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Assets |
0
N/A
|
0
N/A
|
1
N/A
|
44
+3 007%
|
36
-16%
|
220
+504%
|
239
+9%
|
206
-14%
|
74
-64%
|
38
-48%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
0
|
0
|
2
|
5
|
4
|
5
|
10
|
14
|
16
|
|
| Accrued Liabilities |
0
|
0
|
1
|
3
|
3
|
7
|
12
|
22
|
13
|
6
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
0
|
1
|
|
| Total Current Liabilities |
0
|
0
|
2
|
5
|
9
|
12
|
17
|
33
|
27
|
22
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
93
|
101
|
103
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
2
|
7
|
|
| Total Liabilities |
0
N/A
|
0
+50%
|
2
+667%
|
5
+104%
|
10
+102%
|
13
+39%
|
18
+35%
|
129
+625%
|
130
+1%
|
131
+1%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
0
|
0
|
5
|
24
|
57
|
139
|
246
|
412
|
591
|
650
|
|
| Additional Paid In Capital |
0
|
0
|
4
|
63
|
84
|
346
|
467
|
488
|
534
|
557
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
0
-50%
|
1
-233%
|
39
N/A
|
27
-31%
|
207
+668%
|
222
+7%
|
77
-65%
|
57
N/A
|
93
-65%
|
|
| Total Liabilities & Equity |
0
N/A
|
0
N/A
|
1
N/A
|
44
+3 007%
|
36
-16%
|
220
+504%
|
239
+9%
|
206
-14%
|
74
-64%
|
38
-48%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
3
|
|
Switch to:
Switch to:
See Also
Discover More
